StockData
GT Biopharma, Inc. logo

GT Biopharma, Inc. (GTBP) stock

GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$2.96−0.22 (-6.92%)

Close on Nov 20, 2026Market cap $133.52MP/E –Yield –

GT Biopharma net income

Net income is the profit left for shareholders after every expense, interest and tax.

GT Biopharma's net income for the twelve months ending Jun 30, 2026 was -$4.76M. For fiscal 2025 it was -$28.35M. The highest annual figure on record is $9.77M in fiscal 2016.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$28.35M–
FY2024Dec 31, 2024-$13.16M–
FY2023Dec 31, 2023-$7.60M–
FY2022Dec 31, 2022-$20.88M–
FY2021Dec 31, 2021-$58.01M–
FY2020Dec 31, 2020-$28.30M–
FY2019Dec 31, 2019-$38.65M–
FY2018Dec 31, 2018-$259.19M–
FY2017Dec 31, 2017-$144.17M-1576.0%
FY2016Dec 31, 2016$9.77M–
FY2015Dec 31, 2015-$21.46M–
FY2014Dec 31, 2014-$23.49M–
FY2013Dec 31, 2013-$501.00K–
FY2012Dec 31, 2012-$5.17M–
FY2011Dec 31, 2011-$3.70M–
FY2010Dec 31, 2010-$3.00M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.52M–
Q1 FY2026Mar 31, 2026-$2.83M–
Q4 FY2025Dec 31, 2025-$5.71M–
Q3 FY2025Sep 30, 2025$8.30M–
Q2 FY2025Jun 30, 2025-$30.17M–
Q1 FY2025Mar 31, 2025-$776.00K–
Q4 FY2024Dec 31, 2024-$3.78M–
Q3 FY2024Sep 30, 2024-$3.41M–
Q2 FY2024Jun 30, 2024-$3.71M–
Q1 FY2024Mar 31, 2024-$2.27M–
Q4 FY2023Dec 31, 2023-$2.96M–
Q3 FY2023Sep 30, 2023-$2.42M–
Q2 FY2023Jun 30, 2023-$1.99M–
Q1 FY2023Mar 31, 2023-$227.00K–
Q4 FY2022Dec 31, 2022-$5.58M–
Q3 FY2022Sep 30, 2022-$6.88M–
Q2 FY2022Jun 30, 2022-$2.98M–
Q1 FY2022Mar 31, 2022-$5.44M–
Q4 FY2021Dec 31, 2021-$18.02M–
Q3 FY2021Sep 30, 2021-$5.45M–
Q2 FY2021Jun 30, 2021-$4.86M–
Q1 FY2021Mar 31, 2021-$29.68M–
Q4 FY2020Dec 31, 2020-$6.29M–
Q3 FY2020Sep 30, 2020-$2.88M–
Q2 FY2020Jun 30, 2020-$17.42M–
Q1 FY2020Mar 31, 2020-$1.71M–
Q4 FY2019Dec 31, 2019-$1.47M–
Q3 FY2019Sep 30, 2019-$29.88M–
Q2 FY2019Jun 30, 2019-$2.79M–
Q1 FY2019Mar 31, 2019-$4.51M–
Q4 FY2018Dec 31, 2018-$4.23M–
Q3 FY2018Sep 30, 2018-$235.78M–
Q2 FY2018Jun 30, 2018-$9.08M–
Q1 FY2018Mar 31, 2018-$10.09M–
Q4 FY2017Dec 31, 2017-$6.03M–
Q3 FY2017Sep 30, 2017-$130.63M–
Q2 FY2017Jun 30, 2017-$2.46M–
Q1 FY2017Mar 31, 2017-$5.06M–
Q4 FY2016Dec 31, 2016-$2.83M–
Q3 FY2016Sep 30, 2016-$3.63M–

More GT Biopharma figures

See a number that looks wrong?